Both LY294002 and wortmannin showed unacceptable levels of toxicity in animals and therefore were not developed clinically; however a wortmannin analogue, PX-866, and a conjugate version of LY294002, are both currently being tested in Phase I trials24 - MEK Inhibitors in highly invasive breast cancer cells

Both LY294002 and wortmannin showed unacceptable levels of toxicity in animals and therefore were not developed clinically; however a wortmannin analogue, PX-866, and a conjugate version of LY294002, are both currently being tested in Phase I trials24. better understand the role that Notch signaling and its individual components play in tumor angiogenesis before these pathways … Continue reading Both LY294002 and wortmannin showed unacceptable levels of toxicity in animals and therefore were not developed clinically; however a wortmannin analogue, PX-866, and a conjugate version of LY294002, are both currently being tested in Phase I trials24